These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

259 related articles for article (PubMed ID: 14720083)

  • 21. When should data and safety monitoring committees share interim results in cardiovascular trials?
    Borer JS; Gordon DJ; Geller NL
    JAMA; 2008 Apr; 299(14):1710-2. PubMed ID: 18398083
    [No Abstract]   [Full Text] [Related]  

  • 22. The data and safety monitoring board and acquired immune deficiency syndrome (AIDS) clinical trials.
    DeMets DL; Fleming TR; Whitley RJ; Childress JF; Ellenberg SS; Foulkes M; Mayer KH; O'Fallon J; Pollard RB; Rahal JJ
    Control Clin Trials; 1995 Dec; 16(6):408-21. PubMed ID: 8720018
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Understanding the functions and operations of data monitoring committees: Survey and focus group findings.
    Calis KA; Archdeacon P; Bain RP; Forrest A; Perlmutter J; DeMets DL
    Clin Trials; 2017 Feb; 14(1):59-66. PubMed ID: 27885056
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Pursuit of truly independent data monitoring committees in research.
    Marston L; McKenzie DR; Freemantle N
    BMJ; 2016 May; 353():i2309. PubMed ID: 27172924
    [No Abstract]   [Full Text] [Related]  

  • 25. Survey of professional views on sharing interim results by the Data Safety Monitoring Board (DSMB): what to share, with whom and why.
    Borg Debono V; Mbuagbaw L; Paul J; Buckley N; Thabane L
    Trials; 2018 May; 19(1):281. PubMed ID: 29784030
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Independence of the statistician who analyses unblinded data.
    Siegel JP; O'Neill RT; Temple R; Campbell G; Foulkes MA
    Stat Med; 2004 May; 23(10):1527-9. PubMed ID: 15122732
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Stopping guidelines for harm in a study designed to establish the safety of a marketed drug.
    Fleishman AN; Parker RA
    J Biopharm Stat; 2012; 22(2):338-50. PubMed ID: 22251178
    [TBL] [Abstract][Full Text] [Related]  

  • 28. What is the appropriate role of the trial statistician in preparing and presenting interim findings to an independent Data Monitoring Committee in the U.S. Cancer Cooperative Group setting?
    Bryant J
    Stat Med; 2004 May; 23(10):1507-11. PubMed ID: 15122728
    [TBL] [Abstract][Full Text] [Related]  

  • 29. On the independence of data monitoring committee in adaptive design clinical trials.
    Chow SC; Corey R; Lin M
    J Biopharm Stat; 2012; 22(4):853-67. PubMed ID: 22651119
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Stopping guidelines for an effectiveness trial: what should the protocol specify?
    Tyson JE; Pedroza C; Wallace D; D'Angio C; Bell EF; Das A
    Trials; 2016 May; 17(1):240. PubMed ID: 27165260
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Data safety monitoring boards: legal and ethical considerations for research accountability.
    Tereskerz PM
    Account Res; 2010 Jan; 17(1):30-50. PubMed ID: 20094929
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Forming your phase III trial's data and safety monitoring board: a perspective on safety.
    Wittes J
    J Investig Med; 2004 Nov; 52(7):453-8. PubMed ID: 15651261
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Building a more connected DSMB: better integrating ethics review and safety monitoring.
    Eckstein L
    Account Res; 2015; 22(2):81-105. PubMed ID: 25397600
    [TBL] [Abstract][Full Text] [Related]  

  • 34. [DSMB. 1. What role, what responsibilities?].
    Brun-Buisson C
    Med Sci (Paris); 2005 Jan; 21(1):78-82. PubMed ID: 15639025
    [TBL] [Abstract][Full Text] [Related]  

  • 35. [DSMB. 2. The importance of an efficient DSMB: some examples of high-risk clinical trials].
    Brun-Buisson C
    Med Sci (Paris); 2005 Feb; 21(2):187-9. PubMed ID: 15691491
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Data and Safety Monitoring Board evaluation and management of a renal adverse event signal in TOPCAT.
    Bristow MR; Sharma K; Assmann SF; Linas S; Gersh BJ; Grady C; Rice MM; Singh S; Boineau R; McKinlay SM; Greenberg BH
    Eur J Heart Fail; 2017 Apr; 19(4):457-465. PubMed ID: 27873428
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Maintaining confidentiality of interim data to enhance trial integrity and credibility.
    Fleming TR; Sharples K; McCall J; Moore A; Rodgers A; Stewart R
    Clin Trials; 2008; 5(2):157-67. PubMed ID: 18375654
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Data monitoring committees, interim analysis and early termination in paediatric trials.
    Fernandes RM; van der Lee JH; Offringa M
    Acta Paediatr; 2011 Oct; 100(10):1386-92. PubMed ID: 21434998
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Should data and safety monitoring boards share confidential interim data?
    Dixon DO; Lagakos SW
    Control Clin Trials; 2000 Feb; 21(1):1-6; discussion 54-5. PubMed ID: 10659999
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Role of the Data and Safety Monitoring Committee (DSMC).
    Wilhelmsen L
    Stat Med; 2002 Oct; 21(19):2823-9. PubMed ID: 12325098
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 13.